Dolutegravir sodium是一种高效、口服的HIV 整合酶链转移抑制剂，在 HIV-1 整合酶催化的链转移中的IC50值为 2.7 nM， 抑制 HIV-1 病毒在外周血单个核细胞中的复制，IC50为 0.51 nM。它对 Y143R，N155H 和 G140S/Q148H 突变体也保持高效。

Dolutegravir sodium salt(DTG; GSK1349572) is an HIV integrase inhibitor(IC50: 2.7 nM), modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.

Dolutegravir(S/GSK1349572) inhibits HIV-1 integrase-catalyzed strand transfer with a 50% inhibitory concentration (IC50) of 2.7 nM. S/GSK1349572 inhibits both the HIV integration reaction strand transfer step in vitro and HIV replication in cells with similar potencies. The inhibitor has no effect on total viral DNA synthesis in infected cells but blocks the integration of viral DNA into host DNA with the same potency as its antiviral effect[1].

The bioavailability of dolutegravir was high when administered as a solution, but was limited by dissolution rate or solubility when administered as a suspension. Dolutegravir is the major circulating component in mice, rats, and monkeys, with direct ether glucuronidation shown to be the primary biotransformation pathway. Dolutegravir is primarily eliminated via the feces either unabsorbed or by hydrolysis of the glucuronide or glucose conjugate[2].

In vitro growth inhibition (cytotoxicity) studies are conducted with S/GSK1349572 in proliferating human leukemic and lymphomic cell lines (IM-9, U-937, MT-4, and Molt-4) as well as in stimulated and unstimulated human PBMCs. ATP levels are quantified by using the CellTiter-Glo luciferase reagent to measure the ability of a compound to inhibit cell growth as an indicator of the compound's potential for cytotoxicity.(Only for Reference)

1051375-19-9

C20H18F2N3NaO5

441.367

度鲁特韦钠盐;度鲁特韦钠;GSK1349572;GSK-1349572A

DMSO:10mM
Powder: -20°C for 3 years
In solvent: -80°C for 2 years